Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...
Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs...
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that...
The Medical Device Market is witnessing robust expansion driven by rising healthcare expenditure, growing prevalence of chronic diseases, and accelerating...
IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studiesFirst patient...
WELLINGTON, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Medical Specialists of the Palm Beaches (MSPB), a primary care-focused, multi-specialty physician...
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of...
In this free webinar, gain a strategic lens for building durable, scalable digital biomarker programs that deliver clinical and business...
Facility Growth Adds 30,000 Square Feet to Strengthen Warehouse, Cleanroom Production, and Office Capabilities ALPHARETTA, Ga., Oct. 16, 2025 /PRNewswire/...
LOS ANGELES, Oct. 15, 2025 /PRNewswire/ -- Women are twice as likely as men to develop Alzheimer's disease (AD) and multiple...
NEW YORK, Oct. 15, 2025 /PRNewswire/ -- The Global Digital Health Market is projected to grow from USD 288.55 billion in...
This year's conference represents a first: it brings together an extraordinarily diverse array of experts for a high-level, "get real"...
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy...
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI®...
Distinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision...
CONVOKE was the first and only pivotal trial to show a statistically significant reduction in experiential negative symptoms of schizophrenia...
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in...
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory...
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 9,...
TIME Best Inventions honors extraordinary innovations changing lives DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader...